The Chicago-area medical device company said the Xience Xpedition is approved to treat patients with diabetes and requires only 3 months of dual-antiplatelet drug therapy, which Abbott touted as "the shortest duration required for any major drug eluting stent offered in Europe," according to a press release.
"Long-term compliance to DAPT can be a challenge for patients and can lead to additional safety risks such as increased bleeding events," according to the release. "Having a shorter DAPT duration after stent implantation may be beneficial in case a patient needs to interrupt or discontinue the medication prior to surgery or for other considerations."
In April, Abbott won a regulatory nod in Japan when regulators there approved its Xience Prime cobalt-chromium drug-eluting stent. Now that Johnson & Johnson‘s (NYSE:JNJ) Cordis subsidiary has ceded the coronary stent market to its rivals, Abbott, Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are locked in a 3-way battle to dominate the sector.
Medtronic’s latest salvo also came in April, when it lauded data showing that its Resolute stent proved non-inferior to Abbott’s Xience in an off-label study, including "real world" uses, in patients with complex lesions.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.